Dr. Brian L. Burnette
Claim this profileSaint Vincent Hospital Cancer Center Green Bay
Area of expertise
Breast Cancer
Brian L. Burnette has run 8 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Brian L. Burnette has run 7 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Saint Vincent Hospital Cancer Center Green Bay
Saint Vincent Hospital Cancer Center At Saint Mary's
Clinical Trials Brian L. Burnette is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting
1 award
Phase 2
31 criteria
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting
1 award
Phase 2
7 criteria
More about Brian L. Burnette
Clinical Trial Related
5 years of experience running clinical trials · Led 31 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Brian L. Burnette has experience with
- Carboplatin
- Nivolumab
- Fluorouracil
- Paclitaxel
- Cisplatin
- Pembrolizumab
Breakdown of trials Brian L. Burnette has run
Breast Cancer
Breast cancer
Lung Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian L. Burnette specialize in?
Brian L. Burnette focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are Stage II.
Is Brian L. Burnette currently recruiting for clinical trials?
Yes, Brian L. Burnette is currently recruiting for 13 clinical trials in Green Bay Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Brian L. Burnette has studied deeply?
Yes, Brian L. Burnette has studied treatments such as Carboplatin, Nivolumab, Fluorouracil.
What is the best way to schedule an appointment with Brian L. Burnette?
Apply for one of the trials that Brian L. Burnette is conducting.
What is the office address of Brian L. Burnette?
The office of Brian L. Burnette is located at: Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin 54301 United States. This is the address for their practice at the Saint Vincent Hospital Cancer Center Green Bay.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.